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Abstract: Candida bloodstream infections remain the most frequent life-threatening fungal disease,
with Candida albicans accounting for 70% to 80% of the Candida isolates recovered from infected
patients. In nature, Candida species are part of the normal commensal flora in mammalian hosts.
However, they can transform into pathogens once the host immune system is weakened or breached.
More recently, mortality attributed to Candida infections has continued to increase due to both inherent
and acquired drug resistance in Candida, the inefficacy of the available antifungal drugs, tedious
diagnostic procedures, and a rising number of immunocompromised patients. Adoption of animal
models, viz. minihosts, mice, and zebrafish, has brought us closer to unraveling the pathogenesis
and complexity of Candida infection in human hosts, leading towards the discovery of biomarkers
and identification of potential therapeutic agents. In addition, the advancement of omics technologies
offers a holistic view of the Candida-host interaction in a non-targeted and non-biased manner.
Hence, in this review, we seek to summarize past and present milestone findings on C. albicans
virulence, adoption of animal models in the study of C. albicans infection, and the application of omics
technologies in the study of Candida–host interaction. A profound understanding of the interaction
between host defense and pathogenesis is imperative for better design of novel immunotherapeutic
strategies in future.
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1. Introduction
There are approximately 8.7 million eukaryotic species, with fungal species constituting
approximately 7% (611,000 species) of the total [1]. Fungi can cause diseases ranging from cutaneous
skin infections to lethal acute or chronic infections of deep tissues. There are an estimated 600 fungal
species that are human pathogens, including Candida species [2].
Candida originates from the taxonomical division of ascomycetes and is a fungal genus with
the potential to cause life-threatening systemic infections. It has been characterized as a white
asporogenous yeast capable of forming pseudohyphae or hyphae. Currently, there are seven medically
important Candida species, C. albicans, C. tropicalis, C. glabrata, C. parapsilosis, C. stellatoidea, C. krusei
and C. kefyr, with C. albicans being the most frequent causative agent afflicting humans [3].
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Since the 1970s, the incidence of Candida infection has increased steadily. This increment is caused
by a global increase in the number of patients who are prone to infection and an improvement
in clinical procedures to identify yeasts as the causative agents of nosocomial infections [4].
In immunocompromised individuals, the development of systemic candidiasis is a serious disease
often associated with mortality [5].
Candidiasis is the fourth most identified cause of nosocomial bloodstream infections [6], while
Candida species are the fourth most common cause of bloodstream infections in hospitals in the United
States, with crude mortality rates of up to 50% [7,8]. Of all Candida species, C. albicans remains the most
common species of bloodstream infections in hospitals. C. albicans is responsible for 59% of nosocomial
candidemia and for 55% of bloodstream infections [9–11].
Not surprisingly, the incidence of candidiasis is the highest in intensive care units (ICU) among
patients admitted to hospitals, and accounts for up to 15% of all nosocomial infections [12]. Bouza et al.
reported that an estimated 33%–55% of all candidemia cases occur in the ICU, with mortality rates
ranging from 5% to 71% [13]. Schelenz (2008) reported that Candida albicans is the predominant species
causing candidemia in ICU patients in the United Kingdom [9]. In addition, Enoch et al. reported
that C. albicans is responsible for 79.4% of candidaemias [14]. Candidemia in ICUs is associated with
increased total hospital costs and length of stay, which imposes an extra financial burden on both
individuals and the government.
Hence, the high frequency of Candida infection constitutes a serious clinical problem worldwide.
The high mortality of Candida-related infections in immunocompromised patients is a perpetual
problem caused by the difficulty of diagnosing and treating invasive or systemic candidiasis; thus there
is a dire need for the development of sensitive and specific diagnostic methods and appropriate
strategies for candidiasis treatment. It is hoped that this could be achieved through a deeper
understanding of fungal virulence as well as host immune response.
2. Pathogenesis of Candida albicans
Host tissue invasion is a prerequisite for Candida species pathogenicity and is mediated
by surface-expressed adhesion molecules, particularly specific ligand-receptor interactions and
nonspecific interactions that enable Candida species to attach to a range of eukaryotic tissues [15].
A comparative study on the adherence of differentCandida spp. to human epithelial cells was conducted
and it was found that C. albicans and C. tropicalis adhere much more strongly than relatively less virulent
strains like C. krusei and C. guilliermondii [16]. Adherence of the yeast to mucosal epithelial cells is
a necessary component of the infective process with C. albicans. C. albicans has a specialized set of
proteins known as adhesins that enable it to attach to a range of eukaryotic tissues [15]. The important
components of adhesins are agglutinin-like sequence (ALS) proteins and hypha-associated GPI-linked
protein (Hwp1). There are eight members of the ALS proteins (Als1–7 and Als9). Out of these eight
members, Als3 is especially important for adhesion [17–19]. The ALS3 gene expression is upregulated
in oral epithelial cells in vitro and in vivo vaginal infection with C. albicans [20,21]. Furthermore,
Als3 is demonstrated to contribute towards biofilm formation [22]. More recently, Als3 was found
to be an invasin along with Ssa1 [17,23]. Ssa1, a cell-surface expressed member of the heat shock
protein 70 (Hsp70) family, and ALS3 bind to host E-cadherin, which could lead to endocytosis by
a clathrin-dependent mechanism [17,24]. Meanwhile, Hwp1 serves as a substrate for mammalian
transglutaminases and formed covalent bonds with human buccal epithelial cells that covalently
link C. albicans hyphae to host cells. Previous studies with an Hwp1-deficient mutant and an Hwp1
knockout mutant of C. albicans displayed reduced adherence to buccal epithelial cells and reduced
mortality in an intravenous challenge murine model [25–27].
C. albicans can exist as yeasts or elongated filaments (true hyphal or pseudohyphal) depending
on environmental conditions, nutrients, and temperature [28,29]. This enables C. albicans to become a
successful pathogen that can infect a variety of tissues in a mammalian host. Both yeast and filamentous
forms of C. albicans can be observed in infected tissues during infection. Studies showed that mutants of
Int. J. Mol. Sci. 2016, 17, 1643 3 of 17
C. albicans that lack either the yeast or filamentous form have reduced virulence in animals. The yeast
form of C. albicans is involved in dissemination within tissues and to other hosts and its form is
maintained through the repression of the filamentous form by several transcriptional factors such as
Tup1, Nrg1, and Rfg1 [30,31]. Nonfilamentous C. albicans strains with defective transcriptional factors,
such as efg1 and cph1, have been demonstrated to be less virulent in mouse infection models [32].
Filaments of C. albicans are required for tissue damage and escape killing by macrophages. Carlisle
et al. and Lo et al. found that tissue invasion is associated with C. albicans filamentous forms and
mutants of C. albicans compromised in filamentous form have reduced virulence [32,33]. Similarly,
the homozygous null mutant of Tup1 compromised in filamentous expression was unable to colonize
organs in an experimental disseminated mouse model [34,35], which further suggested that the
filamentous form of C. albicans is critical in tissue colonization and invasion. Furthermore, hyphal
cells have stronger adherence capacity due to the expression of ALS adhesins and display greater
invasiveness into tissues. In addition, hypha-associated proteins such as Ece1, HGC1, and Hyr1 are
important virulence factors. For example, the ablation of HGC1 in cells that grow normally in yeast
form leads to failure in the hyphae production. This is because this protein encodes a hypha-specific
G1 cyclin-related protein [36]. Moreover, the yeast and hyphal forms of C. albicans provoke different
immunological responses. The yeast form favors the formation of T-helper type 1 (Th1) cells, which
have protective effects, while filamentous forms favor the formation of T-helper Type 2 (Th2) cells,
which have been linked to disease progression [37].
Phenotypic switching allows for a transition between alternative cell states and is crucial for
pathogenic fungi to colonize and infect different host niches. Candida albicans displays a white-opaque
switch important in regulating sexual mating [38,39], metabolic preferences [40], and interaction with
the mammalian host immune system [41,42]. In the two alternative phenotypic states, white cells are
round, smooth, and domed colonies, whereas opaque cells are elongated, bean-shaped, flatter, and
darker colonies [43]. The switching between white and opaque states is regulated by the WOR1 gene.
White cells are unable to form opaque colonies in the absence of WOR1, whereas overexpression of
WOR1 forces cells to switch to the opaque state [44–46]. Transcriptional studies reveal that when white
and opaque states are compared, there are more than 450 genes that are differentially regulated [40,47].
Moreover, the differences in these transcriptional profiles between the white and opaque form affect
C. albicans mating efficiency, pathogenicity, and biofilm formation [48]. For example, white cells have
higher virulence in an intravenous challenge mouse model, while opaque cells appear to be more
efficient at the colonization level in a cutaneous model of infection [49,50]. Furthermore, white–opaque
switching may be an adaptive mechanism to assist C. albicans cells in evading the host immune system
as white and opaque cells are differentially phagocytosed by macrophages [42]. On the other hand, the
morphological switching between the yeast and hyphal form contributes to mature biofilm formation,
which is the lethal outcome in Candida infection [51].
Right after adhesion of C. albicans to the cell surface, C. albicans hyphae secrete hydrolases
to facilitate active penetration into host cells and enhance the efficiency of extracellular nutrient
acquisition [52,53]. Fungi such as C. albicans produce secreted aspartyl proteinases (SAPs), which
play a role in supplying nutrients for the Candida cells through protein degradation, facilitating
penetration and invasion into host tissues in addition to evading immune responses [54,55]. This
class of enzyme has been demonstrated to be involved in candidiasis [56]. Catalytic properties
of SAPs lie in the conserved sequence of Asp-Thr-Gly as this sequence provides one-half of the
catalytic machinery of these enzymes [57]. The enzyme of this class is also defined from the Thr-Gly
sequence following the Asp, which is essential for the formation of a unique catalytic conformation.
Interestingly, C. albicans had been reported to possess a family of 10 genes encoding SAPs, which might
explain the pathogenesis of the disease [58]. Correspondingly, SAPs have also been utilized in the
diagnosis of systemic candidiasis as markers of invasive candidiasis via competitive binding inhibition
enzyme-linked immunosorbent assay (ELISA) [10]. The key advantage of using SAP markers of
candidiasis lies in their ability to differentiate simple colonization from invasive disease. In light of
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SAP as a virulent factor, Vilanova et al. exploited C. albicans SAP2 as a potential vaccine candidate in
preventing systemic candidiasis in BALB/c mice [59]. These authors noted that the use of SAP2 protein
conjugated with alum adjuvant conferred efficient immune protection by a 20-fold decrease in the
colonization of kidneys. In addition, the protection also correlated with an increase in serum antibodies,
particularly immunoglobulin G towards SAP2. Based on existing literature on SAP-deficient mutants,
SAP1, SAP2, and SAP3 have been shown to contribute significantly to tissue damage and invasion
of oral epithelium, while SAP4, SAP5, and SAP6 are important for systemic infections caused by
C. albicans [60].
Another family of Candida virulence enzymes are the phospholipases, which consist of four
different classes (PLB-A, PLB-B, PLB-C, and PLB-D) [61]. However, only five members of class
B (PLB1-5) are extracellular and may contribute to pathogenicity. Phospholipase B expression
has been detected immunologically in gastrointestinal and systemic infection and in mucosal
models [58]. The mechanisms of action of phospholipase enzyme are disrupting and breaking down
the phospholipids in host cell membranes, which in turn aid adherence and penetration and finally
invasion of host cells [62]. The family of lipases consists of at least 10 members (LIP1-10) [63,64]. LIP5,
LIP6, LIP8, and LIP9 expression was detected in a mouse model of C. albicans peritonitis [64]. A study
reported that C. albicans strains with lack of Lip8 expression displayed reduced virulence in infected
mice, suggesting that lipases are involved in altering C. albicans pathogenicity [65].
Biofilms of C. albicans are multicellular communities of yeast, pseudohyphae, and hyphae
surrounded by extracellular matrix, which form upon adherence to biotic or abiotic surfaces. Biofilms
are formed in a sequential process. These include the adherence of yeast cells to the substrate, followed
by proliferation of these yeast cells and hyphal cells in the upper part of the biofilm, which is then
followed by accumulation of extracellular matrix material and dispersion of yeast cells from the biofilm
complex [66,67]. There are several genes that induce or regulate the formation of biofilm. These
transcription factors include Bcr1, Tec1, Efg1, and Hsp1 [68]. In addition to that, Nobile and co-workers
reported on novel transcriptional factors involved in regulating biofilm formation, which include Rob1,
Ndt80, and Brg1 [69]. Furthermore, defective biofilm formation resulting from the deletion of any
of these transcriptional regulators (ROB1, BCR1, NDT80, EFG1, TEC1, or BCR1) was observed in an
in vivo rat infection model [69].
Biofilm formation of C. albicans is a huge problem in clinical settings as biofilms on implanted
devices such as catheters, pacemakers, and prosthetic devices enable the fungal cells to have direct
access into the bloodstream for dissemination and establishing life-threatening systemic infection.
The dispersion of yeast cells from the mature biofilm has been demonstrated to directly contribute
to virulence in an experimental mouse model of systemic infection [67]. Another concern about
biofilm formation in clinical settings is that they are highly resistant to antifungal drugs and host
immune factors in comparison with planktonic cells. Factors such as upregulation of efflux pumps,
upregulation of oxidative stress, changes in membrane sterol composition, and increased cell density
might contribute to the resistance of biofilm to antifungal drug treatment [68].
Contact sensing and thigmotropism (response to both abiotic and biotic surfaces) are important for
pathogenicity. The environmental factors provide signals to trigger the hypha and biofilm formation in
C. albicans. The yeast cells will then switch to hyphal growth upon surface contact [70]. These hyphae
have the potential to invade into the substratum when in contact with substrates such as mucosal
surfaces or agar. Biofilm formation can also be induced due to contact with solid surfaces [70].
pH sensing has also been discovered to be vital in pathogenicity mechanism. C. albicans must get
used to pH changes in its surroundings as it is exposed to a range of pH from alkaline to acidic in the
human host [71]. The two cell wall β-glycosidases, namely PHR1 and PHR2, are important proteins in
the adaptation to pH changes. PHR1 and PHR2 are expressed in neutral-alkaline pH and acidic pH,
respectively [72,73].
Clearly, C. albicans has evolved into a highly successful microorganism with the ability to colonize
and infect the human host through a plethora of virulence determinants and adaptation mechanisms.
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Hence, a better understanding on the pathogenicity of C. albicans during the infection process will
enable us to spawn new ideas on improving the diagnosis of fungal infection or developing new
antifungal regimens. For example, Candida virulence factors that are crucial in dimorphism, adhesion,
and tissue invasion as well as hydrolytic proteases have been proposed as attractive targets and
promising antifungal therapy [74,75].
3. C. albicans Infection in Animal Models
Several animal hosts have been used to investigate events such as invasion and colonization
by Candida species. These common host systems include mice, fruit flies, nematodes, and zebrafish.
Each model has its own advantages and limitations. Hence, it is important for researchers to choose a
suitable animal model that fits the experimental design and hypothesis that are being tested. In this
review, we will discuss some of the animal models involved in the study of C. albicans infection.
Several mini-host models, viz. the fruit fly (Drosophila melanogaster), nematode (Caenorhabditis
elegans), and wax moth (Galleria mellonella) [76–78], were adopted for C. albicans study. The
D. melanogaster model has been employed in many studies to study, for instance, Candida virulence
and mutants and the efficacy of antifungal drugs [77], to investigate cell-mediated innate immunity
against C. albicans [79], and to probe the links between nutrient availability in infected hosts and
Candida virulence [80]. These studies suggest that D. melanogaster is a suitable model for large-scale
studies of antifungal drug activity, virulence mechanisms, and cell-mediated innate immunity in
candidiasis. On the other hand, the C. elegans model has also often been used in the screening and
development of new antifungal chemical compounds [81], to study Candida virulence factors [68],
and to examine antifungal innate immunity [82]. Like the D. melanogaster and C. elegans models, the
G. mellonella model has been employed in many studies, including experiments on Candida albicans
mutants and virulence [83,84], Candida virulence factors [85–87], C. albicans virulence transcriptional
factors [88], photodynamic therapy (PDT) as a treatment regimen for Candida infections [89], and
the evaluation of the efficacy of antifungal agents [90]. Overall, the adoption of these mini-hosts in
C. albicans infection studies provides a number of advantages. Firstly, these mini-hosts are relatively
inexpensive care systems in contrast to animal models. Secondly, they are highly amenable to
large-scale studies of virulence factors with well-developed molecular tools. In addition, they are an
efficient high-throughput drug screening platform and have conserved innate immunity. However,
the major drawback of these mini-hosts is that they lack adaptive immunity, and so cannot reflect the
real situation of complex fungal pathogenesis and host–pathogen interaction.
Besides these mini-hosts, animal models are used to study the molecular and cellular basis of
pathogenesis of candidiasis and allow the ideal study of host–pathogen interactions under a tightly
controlled environment as the tissue samples are easily harvested unlike studies on human patients,
which present a myriad of complexities. Moreover, the patterns of tissue damage in targeted organs
and overall disease pathology and progression in animal models are closely related to humans’ specific
immune and hormonal responses [91,92].
The murine model is one of the predominant animal models in C. albicans infection studies due
to its direct implications for human systems [93]. Murine models have been widely used in the
study of oral, vaginal, and systemic Candida infection as they mimic human Candida infection [94–96].
The murine challenge intravenous model is considered the “Gold Standard” in the study of systemic
Candida infection [97]. The process for establishing this disseminated infection involves the intravenous
injection of Candida cells into the lateral tail vein of mice, which mimics Candida bloodstream infection
in humans. This model can be used to verify genetic determinants of Candida virulence, host–pathogen
interaction, and the efficacy of new antifungal drugs. The murine model has also been widely used
in the study of oral candidiasis. The advantage of the murine oral candidiasis model is that it only
shows typical lesions that are related to local symptoms of oral candidiasis, allowing more precise
quantification of the disease burden [94]. In addition, employment of a murine model further enhances
our understanding of host–pathogen interactions in oral candidiasis. For example, Th17 helper T cells
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and their secreted cytokine IL-17 have been revealed to have a protective role against oral candidiasis.
The benefits of murine models of candidiasis include the high similarity to human infection due to
the immune system response, which is far superior than using mini-hosts; and the ability to study
whole-organ and systemic host response as well as disease pathology. However, some of the drawbacks
of adopting mice models include excessive experimental costs, inherently unethical practices, and a
limited number of offspring produced for large-scale studies.
Other than mini-hosts and murine models, zebrafish (Danio rerio) have also been used in the study
of Candida pathogenesis and virulence. Embryonic zebrafish were used to study C. albicans morphology
changes and its link to gene expression and early host response towards this pathogen [98]. Since a
zebrafish embryo is transparent, researchers can perform real-time visualization of host–pathogen
interactions [99], thus enabling researchers to monitor and track the changes simultaneously in real
time in both the pathogen and host, which in turn generates a more precise and accurate interpretation
of the host–pathogen interactions. Meanwhile, Brothers et al. used larval zebrafish to study the role of
phagocyte oxidase in limiting filamentous growth of C. albicans and reported that NADPH oxidase is
essential for the control of C. albicans filamentation in vivo [100]. Chen et al. also used zebrafish to study
host–pathogen interactions in C. albicans [101]. In a subsequent study, Chen et al. utilized zebrafish
eggs to study the gene functions in C. albicans and proposed that the zebrafish model is cost-effective
and time-saving [102]. The advantage of using the zebrafish model is that it is less invasive compared
to animal models. Since zebrafish larvae and embryos are transparent in nature, non-invasive imaging
techniques can be used for studies like genetic manipulation or pharmacological treatment. These
less intrusive techniques can minimize animal suffering and improve experimental outcomes. Besides
that, the zebrafish has a high reproductive rate, which makes it suitable for large-scale studies, and
the availability of comprehensive molecular tools for analyzing the results produced makes it more
economical due to low maintenance costs [103]. Moreover, unlike mini-hosts that lack adaptive
immunity, zebrafish comprises both innate and adaptive immunity, and mimics mammals in the
context of anatomy, physiology, and genetics [104].
Therefore, it is imperative to understand the intricate interaction between host and pathogen
through the adoption of animal models infected with Candida species as it will enable us to consolidate
our knowledge of how the pathogen interacts with and influences host cell function, which simulates
the transition from asymptomatic colonization to symptomatic infection in humans. This will
eventually lead to the development of effective antifungal drugs for treating Candida infection.
4. Omics Perspective on Candida–Host Infection
Due to advancements in the areas of innate and regulatory immunology, host–pathogen
interaction has become the “epitome” of biomedical research. In addition, with the advancement of
omics technology and the development of advanced systems biology tools, researchers can approach
host–pathogen interaction during Candida infection in an unprejudiced and quantitative manner.
The host–pathogen interaction is a very complicated process, and much remains to be fully
elucidated to dissect the different aspects of C. albicans virulence and unravel its interactions with the
innate immune system and the contribution of each of these events to C. albicans pathogenesis, which
may ultimately lead to better therapeutics that can target the cellular response to infection.
5. Transcriptomics
There have been numerous transcriptomic studies on the interactions between host and C. albicans.
By using microarray analysis, Kim et al. reported that the co-culture of human monocytes with
C. albicans resulted in upregulation of genes involved in production of proinflammatory cytokines,
interleukins, and tumor necrosis factor-α [105]. In addition, primary human endothelial cells were
found to upregulate 56 genes that predominantly consist of chemotaxis, cell death, and cell signaling
related genes against C. albicans in vitro [106]. Interestingly, a study by our group comparing the
transcriptomic profiles of low- and high-density C. albicans-infected human umbilical vein endothelial
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cells (HUVECs) revealed that genes involved in apoptosis and cell death were significantly differentially
expressed. Our results challenged the conventional belief that the yeast form is avirulent and merely
plays a role in dissemination [107]. Using zebrafish, Chen et al. studied the host–pathogen interaction
in C. albicans and categorized C. albicans infection into three stages, namely adhesion, invasion, and
damage. In addition, there is activation of the filamentous formation during invasion phase and
iron scavenging roles during the damage phases in C. albicans. The expression of the majority of the
immune-related genes was seen during the progression of infection from invasion to damage [101].
On the other hand, in whole-organ response during systemic C. albicans infection, MacCallum
(2009) demonstrated that the host response in the kidney against both virulent and attenuated
C. albicans strains mainly involved acute-phase response, coagulation cascade, and complement.
In addition, MacCallum (2009) reported that infection with a virulent strain of C. albicans induces host
immune responses in the kidney, mainly innate immunity, while infection with an attenuated strain
of C. albicans was associated with non-immune responses such as metabolic pathways. MacCallum
et al. (2009) deduced that early-expressed chemokines were important in predicting the kidney’s
immunopathology during systemic C. albicans infection [108]. In another study by Chin et al. (2014),
our research group suggested that pathogenesis of systemic C. albicans infection involved multiple
stages and demonstrated organ-specific host immune responses, mainly innate immune response
towards C. albicans infection [93].
Barker et al. (2008) demonstrated that infection with C. albicans induces specific endothelial cell
responses, not confined to upregulation of host immune genes [109]. Other non-immune responses
such as angiogenesis, stress response, and inhibiting apoptosis were reported, likely caused by
C. albicans-induced damage to the endothelial cells. Mice infected with C. albicans were reported to have
endothelial cell proliferation in the regions adjacent to microabscesses in the kidney and brain [110],
and the proliferation of endothelial cells was likely caused by expression of genes that inhibit apoptosis
and stimulate angiogenesis. In addition, Jose et al. (2013) reported an increase in anti-apoptotic
signal, which is Bcl12 family member Myeloid cell leukemia 1 (Mcl1) [111]. Mcl1 is involved in
promotion of cell viability during phenotypic transition which includes stimulation of differentiation
or proliferation [112]. Another anti-apoptotic signal includes the increase in phosphorylation of
nucleophosmin (NPM), a nucleolar phosphoprotein that binds the tumor suppressors p19Arf and p53.
NPM is important for cell proliferation, ribogenesis and survival after DNA damage [113].
Taken together, the majority of the previous studies have shown that the innate immunity
mediated by neutrophils, macrophages, and monocytes is crucial in pathogen detection, antimicrobial
defenses, the activation of the adaptive immune system, and eventually controlling the disease
outcome. Nonetheless, findings from Barker et al. (2008) suggested that the role of angiogenesis
should be investigated in the pathogenesis of disseminated candidiasis, and the contribution of other
non-immune response pathways besides classical immune response pathways should be explored
further to better understand the host defense against Candida [109]. On the other hand, the inhibition
of apoptosis could be a host immune mechanism reinforcing defenses by maintaining active and viable
macrophages against C. albicans. However, the inhibition of apoptosis could become another C. albicans
putative virulence factor if the infected macrophages favor the replication and dissemination of the
C. albicans that remain alive inside them. Subsequently, it will be interesting to determine whether the
anti-apoptotic response is regulated by the pathogen or by the macrophages.
By using RNA sequencing and siRNA technology, Liu et al. (2015) further improved our
understanding of the interaction between C. albicans infection and host response. In their study,
transcriptional profiles of both C. albicans and host cells during in vitro infection of oral epithelial and
vascular endothelial cells were analyzed. A number of signaling proteins that were not previously
linked with the host response to any pathogenic fungus were uncovered via a network analysis
of the dataset. The authors also deduced that neural precursor-cell-expressed developmentally
downregulated protein 9 (NEDD9) and platelet-derived growth factor BB (PDGF BB) govern the
host–pathogen interaction by regulating the uptake of C. albicans by host cells [114].
Int. J. Mol. Sci. 2016, 17, 1643 8 of 17
6. Genomics
Genetic susceptibility to Candida diseases has generated much interest lately [115]. Smeekens
and his research group have reported that Candida susceptibility caused by various genetic variants
are found in downstream signaling molecules and pathogen recognition or cytokine receptors [116].
In addition, a genome-wide association study (GWAS) with 217 human candidemia patients performed
by Kumar et al. discovered that SNPs in CD58, LCE4A, and TAGAP will elevate the risk for
candidemia [117].
7. Proteomics
Transcriptomic studies can provide new insights on host–pathogen interaction; however,
the findings from transcriptomic studies only pertain to the gene level, while certain effectors might
not be expressed in cells and thus cannot fully reflect the active effectors or molecules in an organism.
Therefore, proteomic analyses of the interaction of C. albicans with host immunity is crucial to elucidate
the molecular interplay of host immune defence mechanisms, to understand how C. albicans can escape
from host immunity, and to identify antigenic proteins during Candida–host interaction that could
serve as diagnostic or prognostic markers and therapeutic interventions in the near future.
Vialás et al. first established a database named Proteopathogen, a protein database that focuses on
C. albicans–host interaction [118]. Proteopathogen initially emphasized C. albicans and its interaction
with macrophages and a subsequent version, Proteopathogen2, expanded on that concept and included
the adoption of the HUPO-PSI standards [119]. It also includes information on proteomics experimental
data and proteomic workflows. Martínez-Solano et al. studied the differential expression of proteins in
macrophages upon interaction with wild-type strain C. albicans SC5314, in a murine macrophage cell
line RAW 264.7 [120]. In the study, the authors reported that the expression of LyGDI, annexin I, Hspa5,
L-plastin, and tropomyosin 5 were augmented while the expression of eif3s5, grp58, Hspa9a, Hsp 60,
and Hspa8a were reduced. These differential findings indicate that many processes are affected, viz.
protein biosynthesis and refolding, oxidative responses, and cytoskeletal organization. In another
study by Martínez-Solano et al., the authors studied the interaction of macrophage RAW 264.7 with
heat-inactivated C. albicans cells and revealed that the overall response involved was anti-inflammatory.
The authors also postulated that the differential proteomic response from a macrophage could depend
on the status of C. albicans cells, either alive or heat-inactivated [121]. Reales-Calderón et al. investigated
the interaction between RAW 264.7 macrophages and C. albicans through quantitative proteomics
and phosphoproteomics approaches. Reales-Calderón and co-workers reported that macrophage
responses against C. albicans involved the inflammatory proteins and expression of proteins related
to oxidative stress including receptors, cytoskeletal proteins, mitochondrial ribosomal proteins, and
transcription factor activators. Furthermore, the authors also identified proteins related to apoptosis in
the study and through analysis of apoptotic markers; anti-apoptotic signals were strong and hence
the authors suggested that, apart from inflammation, the apoptosis pathway is crucial in host defense
against C. albicans [122]. In the following year, Reales-Calderón and co-workers [123] studied the
differential proteome expression between human M1 and M2 macrophages upon stimulation with
C. albicans. The findings revealed that the substantial differences between M1 and M2 macrophages
were found in metabolic and cytoskeletal rearrangement routes. In addition, the authors found that
fructose-1,6-biphosphatase 1, an important enzyme involved in gluconeogenesis, is upregulated in
M1 macrophages. Furthermore, upon interaction with C. albicans, the authors observed an M1-to-M2
switch in polarization. This switching exacerbates Candida pathogenicity by diminishing the immune
responses, which in turn increase fungal survival and colonization or an attempt by the host to mitigate
the damage caused by inflammation [123].
Kitahara et al. analyzed the escaping behavior of C. albicans from macrophages by using mixed
and quantitative proteome analysis in isolation [124]. The authors identified five proteins from
macrophages and 237 proteins from C. albicans as candidate interaction-specific molecules. The authors
reported that macrophage-induced C. albicans proteins were linked with stress response, membrane
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synthesis, glucose generation, and other unknown functions. Meanwhile, C. albicans-induced
macrophage proteins were linked with a chaperone and apoptosis. The authors postulated
that C. albicans can endure the harsh environment inside macrophages through upregulation of
stress-related proteins, while the escape of C. albicans from macrophages could be associated with the
production of glucose from a β-oxidation pathway and downregulation of chaperone HSPA1A- and
apoptosis-associated protein, NOA1-syntheses, in macrophages [124]. In summary, proteome research
on host–pathogen interaction with respect to Candida infection is still an emerging field. More
comprehensive and large-scale research is needed in the future to unravel the mechanisms of
pathogenicity and Candida virulence.
8. Computational Systems Biology
The advancement of omics technologies in previous years augments the demands of computational
assistance to analyze omics data. In fungal immunity, these omics data may include transcriptomic,
proteomic, and metabolomic findings to generate interaction networks at the host–pathogen level,
which can be used to predict the outcome of infection. Furthermore, datasets from host–pathogen
interaction were obtained from direct experimentation quantification and there was no linkage between
these datasets. Hence, computational systems biology provides a platform to link these datasets from
various parameters to identify key characteristics of host–pathogen interactions.
Computational systems biology is an emerging area in fungal immunity study. Hünniger and
co-workers (2014) investigated the innate effector mechanisms and Candida albicans immune escape
in human blood through experimental and computational models. Firstly, the authors analyzed the
innate immune response against C. albicans by adding fungal cells into human whole blood and found
that the predominant immune response was associated with neutrophils, with a minority mediated by
monocytes. The authors then developed a virtual C. albicans infection model that permitted detailed and
quantitative predictions on the dynamics of Candida–host interaction in whole blood. The time-resolved
data were designed and simulated by a state-based modeling approach that was combined with the
Monte Carlo method of simulated annealing to identify the main components of antifungal immunity
and to obtain quantitative predictions on a priori unknown transition rates. The authors concluded
that in human blood, neutrophils were predominant in killing and eliciting an immune response
against C. abicans, mediated through intracellular killing and phagocytosis; and that the escape of
C. albicans from immune response was independent of filamentation, inactivation, or exhaustion of
innate immune cells. The resistance of C. albicans cells to phagocytosis could lead to dissemination in a
bloodstream infection. In addition, the authors also suggested that this experiment–model–experiment
cycle is useful in quantitative analyses of host–pathogen interaction in a complex environment like
human blood [125].
On the other hand, Dühring et al. [126] gave an overview of host defense strategies, which include
immunological mechanisms and general stressors as well as fungal evasion mechanisms, and the
adoption of computational systems biology approaches to investigate these complex interactions
through agent-based models and game-theoretical methods. In addition, Durmus¸ et al. summarized
the available literature on the computational analysis of PHI (Pathogen–Host Interaction) networks,
including PHI network inference using omics data, computational prediction of PHIs, text mining of
PHI data and mathematical modeling, and bioinformatic analysis of PHIs [127]. Remmele and his
co-workers constructed a PHIs network analysis of C. albicans and reported that Eno1, phospholipase
B (PLB1), Hsp70, and pyruvate kinase (CDC19) are among the Candida virulence factors that interact
with host factors CD4, Alb and amyloid beta (A4) precursor protein (APP), Toll-like receptor 2 (Tlr2),
and epidermal growth factor receptor (Egfr), respectively. This integrated network will be useful
for high-throughput analysis of host–pathogen transcriptome and proteome data in the future [128].
On the other hand, Dix et al. constructed a random forest classifier to determine whether a sample
contains a fungal, bacterial, or mock infection by using transcriptomic data obtained from the
interaction of bacteria pathogens Staphylococcus aureus and Escherichia coli and the fungal pathogens
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Candida albicans and Aspergillus fumigatus in a human whole-blood model [129]. This analysis provides
new insights into systemic host responses and may ultimately lead to the development of new
anti-microbial regimens. Lehnert et al. [130] constructed a bottom-up modeling approach, from a
state-based model to an agent-based model, to simulate C. albicans infection in a human whole-blood
model. The authors reported that polymorphonuclear neutrophils (PMN) cells are important effector
cells in killing C. albicans in human blood. The authors also surmised that a systemic medicine approach
that utilizes the predictive power of virtual infection models will play a crucial role in infectious disease
diagnosis in the future [130].
The potential of computational tools in predicting the host survival in C. albicans infection was
explored by Peltz and his research group through a combination of computation and experimental
models. In the study, a next-generation computational genetic mapping program with advanced
features was developed. The computational analysis revealed that early classical complement pathway
components (C1q, C1r, and C1s) could affect the survival of mice in a murine genetic model of
hematogenous C. albicans infection. Experimental study further substantiates the computational
results, wherein the binding of serum C1 to C. albicans and the survival of chromosome substitution
strains was greatly influenced by C1rs alleles. The authors concluded that a combination of a
next-generation computational genetic mapping program and an experimental murine genetic model
accurately predicted survival after C. albicans infection, which involves an interaction between C5 and
C1r/s alleles. Furthermore, it was also suggested that this combinatorial, conditional genetic model
could enhance our knowledge of the genetic factors affecting susceptibility to neurodegenerative,
autoimmune, and infectious diseases [131].
In summary, computational modeling of PHIs networks is still in its infancy due to a scarcity of
data. However, the modeling of large amounts of data obtained from transcriptomic, proteomic, and
metabolomic studies can help us to better understand the mechanism of infection, discover biomarkers
for disease diagnosis, and identify novel therapeutic agents for treating infectious diseases.
9. Challenges Apart from Omics and Systems Biology Approaches
Owing to the advancement of omics technology and systems biology, there are still challenges
in the analysis of the host–pathogen system. Krüger et al. [132] addressed some of the challenges
that need to be considered when conducting proteomic analysis of the direct interaction between
phagocytic immune effector cells and fungi, including the enormous complexity of proteins that include
expanded dynamic ranges, selection of suitable blood donors for the study, selection of an appropriate
multiplicity of infection (MOI) to avoid downgrading of the result of relative quantitative analysis, the
demands on isolation procedures for immune effector cells, the demands on culture conditions for
immune effector cells, and the homogeneity of the cell suspensions used for inoculation [132].
Transcriptomic profiles might be useful in fungal diagnostics in the future. Several studies
reported that Candida infection can be discerned from bacterial infection depending on the induced
transcriptome profile [133,134]. However, certain challenges need to be taken into consideration.
The transcriptomic profiles should be replicated in independent studies and involve large samples of
candidemia patients for validation. Furthermore, an additional challenge is that transcriptome studies
are quite time-consuming and costly. The data generated from transcriptome studies is complicated,
and standardization and validation are required between each study [135].
Careful design of experimental protocols is needed when fungal studies are involved. This is due
to the unique fungal anatomy, especially the fungal cell wall, which may result in the inefficacy of some
experiments. The fungal cell wall may interfere with fungal cell lysis, which could lead to incomplete
lysis of fungal cells. Moreover, Culibrk et al. (2006) found that the fungal cell wall may interfere with
the metabolic labeling necessary for techniques such as SUnSET or SILAC [136]. On the other hand,
omics and systems biology studies involve the usage of new and high-throughput technologies. Many
of these techniques have been recently reported and are yet to be validated for accuracy and specificity.
Hence, challenges arise when these new technologies are employed in the laboratory.
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10. Conclusions
C. albicans remains one of the most common fungi, causing high mortality and morbidity in
immunocompromised patients. This review article highlights the important factors contributing to
C. albicans virulence, the advantages and drawbacks of various animal models adopted for C. albicans
pathogenesis, and the application of omics technologies, particularly transcriptomics, proteomics, and
computational systems biology in Candida–host interaction. As systems biology encompasses all omics
approaches, it is highly valuable for unraveling the complexity of Candida–host interaction and for the
design of improved therapeutic regimens. As we look to the future, we can anticipate an exponential
increase of data from the application of these new technologies, ultimately aiding us in attaining a
more holistic understanding of the complex relationship between fungi and humans.
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